Arylamine N-acetyltransferase I expression in breast cancer cell lines: A potential marker in estrogen receptor-positive tumors

Genes Chromosomes and Cancer

Volumn 47, Issue 2, 2008, Pages 118-126

  Wakefield, Larissa ^a   Robinson, James ^a   Long, Hilary ^a   Ibbitt, J Claire ^b,c   Cooke, Susanna ^b   Hurst, Helen C ^c   Sim, Edith ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CELL PROTEIN; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL STRAIN; CELL STRAIN MCF 7; CELL STRAIN ZR 75 1; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DNA MICROARRAY; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NAT1 GENE; POLYADENYLATION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; STRAIN DIFFERENCE; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ARYLAMINE N-ACETYLTRANSFERASE; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; ISOENZYMES; PROGNOSIS; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 38049061726     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20512     Document Type: Article

References (51)

1. Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, De Belin J, Steers G, Pezzella F, Sachsenmeir KF, Stamps AC, Herath A, Sim E, O'Hare MJ, Harris AL, Terrett JA. 2003. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to Etoposide in vitro. Mol Cancer Res 1:826-835.
2. Barker DF, Husain A, Neale JR, Martini BD, Zhang X, Doll MA, States JC, Hein DW. 2006. Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenet Genomics 16:515-525.
3. Bell DA, Badawi AF, Lang NP, Rett KF, Kadlubar FF, Hirvonen A. 1995. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: Association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 55:5226-5229.
4. Bieche I, Girault I, Urbain E, Tozlu S, Lidereau R. 2004. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor α-positive postmenopausal breast carcinoma. Breast Cancer Res 6:R252-R263.
5. Boukouvala S, Fakis G. 2005. Arylamine N-acetyltransferases: What we learn from genes and genomes. Drug Metab Rev 37:511-564.
6. Boukouvala S, Sim E. 2005. Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. Basic Clin Pharmacol Toxicol 96:343-351.
7. Bruhn C, Brockmoller J, Cascorbi I, Roots I, Borchert HH. 1999. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 58:1759-1764.
8. Butcher NJ, Arulpragasam A, Pope C, Minchin RF. 2003. Identification of a minimal promoter sequence for the human N-acetyltransferase type 1 gene that binds AP-1 (activator protein 1) and YY-1 (Yin and Yang 1). Biochem J 376:441-448.
9. Butcher NJ, Arulpragasam A, Goh HL, Davey T, Minchin RF. 2005. Genomic organization of human arylamine N-acetyltransferase type I reveals alternative promoters that generate different 5′-UTR splice variants with altered translational activities. Biochem J 387:119-127.
10. Butcher NJ, Tetlow NL, Cheung C, Broadhurst GM, Minchin RF. 2007. Induction of human arylamine N-acetyltransferase type 1 by androgens in human prostate cancer cells. Cancer Res 67:85-92.
11. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW. 2006. Genomic and transcriptional aberrations linked to breast cancer pathophysiologics. Cancer Cell 10:529-541.
12. Coroneos E, Gordon JW, Kelly SL, Wang PD, Sim E. 1991. Drug metabolising N-acetyltransferase activity in human cell lines. Biochim Biophys Acta 1073:593-599.
13. Dias Neto E, Correa RG, Verjovski-Almeida S, Briones MR, Nagai MA, da Silva W Jr, Zago MA, Bordin S, Costa FF, Goldman GH, Carvalho AF, Matsukuma A, Baia GS, Simpson DH, Brunstein A, de Oliveira PS, Bucher P, Jongeneel CV, O'Hare MJ, Soares F, Brentani RR, Reis LF, de Souza SJ, Simpson AJ. 2000. Shotgun sequencing of the human transcriptome with ORF-expressed sequence tags. Proc Natl Acad Sci USA 97:3491-3496.
14. Dolled-Filhart M, Ryden L, Cregger M, Jirstrom K, Harigopal M, Camp RL, Rimm DL. 2006. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 12:6459-6468.
15. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ. 1978. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 38:3352-3364.
16. Estrada-Rodgers L, Levy GN, Weber WW. 1998. Characterization of a hormone response clement in the mouse N-acetyltransferase 2 (Nat2*) promoter. Gene Expr 7:13-24.
17. Fiegler H, Carr P, Douglas EJ, Burford DC, Hunt S, Scott CE, Smith J, Vetrie D, Gorman P, Tomlinson IP, Carter NP. 2003. DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAG and PAC clones. Genes Chromosomes Cancer 36:361-374.
18. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R. 1997. Human acetyltransferase polymorphisms. Mutat Res 376:61-70.
19. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS. 2001. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61:5979-5984.
20. Hein DW. 2002. Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat Res 506/507:65-77.
21. Hess KR, Anderson K, Symmans WE, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L. 2006. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-4244.
22. Hickman D, Risch A, Buckle V, Spurr NK, Jeremiah SJ, McCarthy A, Sim E. 1994. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 297 (Part 3):441-445.
23. Huang Z, Desper R, Schaffer AA, Yin Z, Li X, Yao K. 2004. Construction of tree models for pathogenesis of nasopharyngeal carcinoma. Genes Chromosomes Cancer 40:307-315.
24. Hughes NC, Janezic SA, McQueen KL, Jewett MA, Castranio T, Bell DA, Grant DM. 1998. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 8:55-66.
25. Ing NH. 2005. Steroid hormones regulate gene expression posttranscriptionally by altering the stabilities of messenger RNAs. Biol Reprod 72:1290-1296.
26. Jonsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, de Jong P, Oredsson S, Ringner M, Hoglund M, Borg A. 2007. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 46:543-558.
27. Lacroix M, Leclercq G. 2004. Relevance of breast cancer cell lines as models for breast tumours: An update. Breast Cancer Res Treat 83:249-289.
28. Lee JH, Chung JG, Lai JM, Levy GN, Weber WW. 1997. Kinetics of arylamine A-acetyltransferase in tissues from human breast cancer. Cancer Lett 111:39-50.
29. Lee JH, Lu HF, Wang DY, Chen DR, Su CC, Chen YS, Yang JH, Chung JG. 2004. Effects of tamoxifen on DNA adduct formation and arylamines N-acetyltransferase activity in human breast cancer cells. Res Commun Mol Pathol Pharmacol 115/116:217-233.
30. Lu KH, Lin KL, Hsia TC, Hung CE, Chou MC, Hsiao YM, Chung JG. 2001. Tamoxifen inhibits arylamine N-acetyl transferase activity and DNA-2-aminofluorene adduct in human leukemia HL-60 cells. Res Commun Mol Pathol Pharmacol 109:319-331.
31. Matas N, Thygesen P, Stacey M, Risch A, Sim E. 1997. Mapping AAC1, AAC2 and AACR the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenet Cell Genet 77:290-295.
32. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. 2005. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102:13550-13555.
33. Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F, Butcher NJ. 2007. Arylamine N-acetyltransferase 1. Int J Biochem Cell Biol 39:1999-2005.
34. Paterson AL, Pole JC, Blood KA, Garcia MJ, Cooke SL, Teschendorff AE, Wang Y, Chin SF, Ylstra B, Caldas C, Edwards PA. 2007. Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event. Genes Chromosomes Cancer 46:427-439.
35. Payton MA, Sim E. 1998. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): The identification of two novel allelic variants. Biochem Pharmacol 55:361-366.
36. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO, Botstein D. 1999. Distinctive gene expression patterns in human mammarv epithelial cells and breast cancers. Proc Natl Acad Sci USA 96:9212-9217.
37. Pole JC, Courtay-Cahen C, Garcia MJ, Blood KA, Cooke SL, Alsop AE, Tse DM, Caldas C, Edwards PA. 2006. High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. Oncogene 25:5693-5706.
38. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL, Brown PO. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 99:12963-12968.
39. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. 2006. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9:121-132.
40. Sim E, Westwood I, Fullam E. 2007. Arylamine N-acetyltransferases. Expert Opin Drug Metab Toxicol 3:169-184.
41. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. 2003. Breast cancer classification and prognosis based on gene expression profiles from a population-based studv. Proc Natl Acad Sci USA 100:10393-10398.
42. Stanley LA, Coroneos E, Cuff R, Hickman D, Ward A, Sim E. 1996. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J Histochem Cytochem 44:1059-1067.
43. Struski S, Doco-Fenzy M, Cornillet-Lefebvre P. 2002. Compilation of published comparative genomic hybridization studies. Cancer Genet Cytogenet 135:63-90.
44. Tanner MM, Tirkkonen M, Kallioniemi A, Isola J, Kuukasjarvi T, Collins C, Kowbel D, Guan XY, Trent J, Gray JW, Meltzer P, Kallioniemi OP. 1996. Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res 56:3441-3445.
45. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R, Bieche I. 2006. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 13:1109-1120.
46. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009.
47. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. 2005. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679.
48. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA Jr, Marks JR, Nevins JR. 2001. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98:11462-11467.
49. Yu K, Ganesan K, Miller LD, Tan P. 2006. A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors. Clin Cancer Res 12:3288-3296.
50. Zhao H, Langerod A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, Bukholm IK, Karesen R, Botstein D, Borresen-Dale AL, Jeffrey SS. 2004. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15:2523-2536.
51. Zhu Y, Wang A, Liu MC, Zwart A, Lee RY, Gallagher A, Wang Y, Miller WR, Dixon JM, Clarke R. 2006. Estrogen receptor α-positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures. Int J Oncol 29:1581-1589.